<DOC>
	<DOCNO>NCT01938833</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose romidepsin give together paclitaxel albumin-stabilized nanoparticle formulation see well work treat patient metastatic inflammatory breast cancer . Romidepsin may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , paclitaxel albumin-stabilized nanoparticle formulation , work different way stop growth tumor cell , either kill cell stop divide . Giving romidepsin paclitaxel albumin-stabilized nanoparticle formulation may effective treatment inflammatory breast cancer .</brief_summary>
	<brief_title>Romidepsin Abraxane Treating Patients With Metastatic Inflammatory Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : 1 . To assess safety combination romidepsin plus Abraxane ( paclitaxel albumin-stabilized nanoparticle formulation ) deliver weekly . ( Phase I ) 2 . To determine maximum tolerate dose ( MTD ) romidepsin full dose weekly Abraxane define recommend phase II dose combination . ( Phase I ) 3 . To assess progression-free survival ( PFS ) patient human epidermal growth factor receptor 2 ( HER2 ) negative , newly diagnose metastatic inflammatory breast cancer treat combination romidepsin Abraxane . ( Phase II ) SECONDARY OBJECTIVES : 1 . To assess safety tolerability combination romidepsin Abraxane . 2 . To determine adverse event profile combination romidepsin Abraxane . 3 . To assess overall response rate ( ORR ) clinical benefit rate ( CBR ) patient newly recurrent inflammatory breast cancer ( IBC ) treat combination romidepsin Abraxane . OUTLINE : This phase I , dose-escalation study romidepsin follow phase II study . Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously ( IV ) 30 minute romidepsin IV 60 minute day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Patients must histologically cytologically confirm breast carcinoma clinical diagnosis IBC base presence inflammatory change involve breast , diffuse erythema edema ( peau d'orange ) , without underlie palpable mass involve majority skin breast . Pathological evidence dermal lymphatic invasion note required diagnosis . 2 . Patients may measurable disease , define least one lesion accurately measure least one dimension accordance RECIST criterion v. 1.1 described detail section 11.0 nonmeasurable tumor 3 . Patients must demonstrate metastatic disease receive &gt; 2 line systemic therapy metastatic disease 4 . Age &gt; 18 year 5 . ECOG performance status 0 , 1 2 6 . Patients must normal organ marrow function define : ) Leukocytes &gt; 2,500/mcL b ) Absolute neutrophil count &gt; 1,500/mcL c ) Hemoglobin &gt; 9 g/dl ) Platelets &gt; 100,000/mcL e ) Total bilirubin &lt; 1.5 mg/dl f ) AST/ALT ( SGOT/SGPT ) &lt; 2.5 x ULN g ) Alkaline Phosphatase &lt; 2.5 x ULN ( unless bone metastasis present absence liver metastasis , case 3.0 x ULN would acceptable . h ) Serum magnesium &gt; 1.8 mg/dL ) Serum creatinine &lt; 1.5 mg/dl j ) Serum potassium &gt; 3.8 mmol/L 7 . Tumor negative HER2 expression ( 0 1+ IHC ) negative FISH test 8 . Patients must life expectancy least 12 week 9 . Patients must recover effect prior surgery , radiotherapy , antineoplastic therapy 10 . Patients must &lt; Grade 2 preexist peripheral neuropathy per CTCAE 11 . Women childbearing potential sexually active male must use effective contraception method treatment three month complete treatment 12 . Negative serum urine βhCG pregnancy test screening , perform 72 hour prior treatment initiation ; patient childbearing potential 13 . Ability understand willingness sign write informed consent HIPAA consent document 1 . Patients chemotherapy radiotherapy within 4 week prior enter study recover adverse event agent administer 4 week earlier 2 . Patients may receive investigational agent active antineoplastic therapy 3 . Patients previously receive romidepsin Abraxane 4 . Patients untreated uncontrolled brain metastasis leptomeningeal disease 5 . Patients know hypersensitivity component romidepsin hypersensitivity reaction paclitaxel 6 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 7 . Any known cardiac abnormality : 1 . Congenital long QT syndrome 2 . QTc interval ≥ 500 millisecond 3 . Myocardial infarction within 6 month C1D1 . Subjects history myocardial infarction 6 12 month prior C1D1 asymptomatic negative cardiac risk assessment ( treadmill stress test , nuclear medicine stress test , stress echocardiogram ) since event may participate 4 . Other significant EKG abnormality include 2nd degree atrioventricular ( AV ) block type II , 3rd degree AV block , bradycardia ( ventricular rate le 50 beats/min ) 5 . Symptomatic coronary artery disease ( CAD ) , e.g. , angina Canadian Class IIIV ( see Appendix III ) In patient doubt , patient stress image study , abnormal , angiography define whether CAD present 6 . An EKG record screen show evidence cardiac ischemia ( ST depression depression ≥2 mm , measure isoelectric line ST segment ) . If doubt , patient stress image study , abnormal , angiography define whether CAD present 7 . Congestive heart failure ( CHF ) meet New York Heart Association ( NYHA ) Class II IV definition ( see Appendix IV ) and/or know ejection fraction &lt; 40 % MUGA &lt; 50 % echocardiogram and/orMRI 8 . A known history sustain ventricular tachycardia ( VT ) , ventricular fibrillation ( VF ) , Torsade de Pointes , cardiac arrest unless currently address automatic implantable cardioverter defibrillator ( AICD ) 9 . Hypertrophic cardiomegaly restrictive cardiomyopathy prior treatment cause 10 . Uncontrolled hypertension , i.e. , blood pressure ( BP ) ≥ 160/95 ; patient history hypertension control medication must stable dose ( least one month ) meet inclusion criterion 11 . Any cardiac arrhythmia require antiarrhythmic medication ( exclude stable dos betablockers ) 12 . Patients take drug lead significant QT prolongation ( See Appendix I : Medications That May Cause QTc Prolongation ) 13 . Concomitant use CYP3A4 inhibitor ( see Appendix II ) 8 . Patients know HIV , hepatitis B C ( However , patient previously treat hepatitis B C undetectable viral load , consider eligible trial ) 9 . Pregnant breast feeding . Refer section 4.4 detail 10 . Patients medical psychological condition deem investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>